TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The American Geriatrics Society has published a case-based framework for clinicians considering obesity medications, including GLP-1 drugs, for older adults. It recommends assessing function, nutrition and cognition before treatment and pairing medication with support such as resistance training and adequate protein intake.
The American Geriatrics Society (AGS) has released a case-based framework to help clinicians make safer, patient-centered decisions about prescribing obesity medications to older adults, a group underrepresented in clinical trials of these drugs. Published in the Journal of the American Geriatrics Society, the paper applies the Geriatrics 5Ms to incretin therapies and urges clinicians to assess patients’ function, nutrition and cognition before treatment.
The framework was developed by the AGS Healthy Aging Special Interest Group and is organized around clinical cases. It addresses obesity medications, including GLP-1 medications that act through gut-derived hormonal pathways. The paper discusses potential benefits for weight management, glycemic control and other health conditions, while emphasizing that prescribing decisions for older adults need to account for age-related risks and individual circumstances.
Its organizing structure is the Geriatrics 5Ms Framework: Mind, Mobility, Medications, Multicomplexity and Matters Most. The paper recommends pretreatment assessment of functional status, nutritional adequacy and cognitive impairment. It also calls attention to sarcopenia and frailty, potential loss of lean muscle, malnutrition and dehydration when clinicians consider treatment.
The authors recommend pairing medication with relevant supportive measures, including resistance training and adequate dietary protein. For some patients, the paper says, care may be best supported by a team that includes a registered dietitian, physical therapist, fitness trainer and behavioral health professional. These are recommendations in a clinical framework, not a report of a trial establishing how well a particular care plan works.
Balancing Weight Treatment With Healthy Aging
The framework speaks to a prescribing challenge: a medication decision for an older adult may involve more than weight or blood sugar. Clinicians may also need to weigh mobility, muscle strength, hydration and nutrition, alongside a patient’s other medications and health conditions. The paper’s approach brings those considerations into the treatment discussion rather than treating age as a single risk factor.
The trial evidence gap adds to that challenge. The source report says older adults are underrepresented in clinical trials of obesity medications. A geriatric framework can help clinicians structure individualized conversations and identify supportive care needs, but it does not fill that evidence gap or show that the medications are safe or beneficial for every older patient.
For patients and caregivers, the practical takeaway is that medication may be only one part of a plan. The framework places patient priorities and day-to-day function within the decision process and highlights nutrition and physical activity as part of care. Whether and how to use a drug still requires an individualized discussion with a clinician.
Products Worth Considering
BowFlex Results Series SelectTech Adjustable Dumbbells (Pair)
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black
Bowflex SelectTech 840 Adjustable Kettlebell
As an affiliate, we earn on qualifying purchases.
The 5Ms Behind the Guidance
The paper, by Elias M. Wisdom and colleagues, is titled “Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing.” It appeared in the Journal of the American Geriatrics Society in 2026, with DOI 10.1111/jgs.70769. Medical Xpress reported the publication on October 30, 2026.
The 5Ms provide a geriatric lens for care: Mind covers cognition and mental health; Mobility concerns movement and function; Medications prompts review of drug treatment; Multicomplexity accounts for interacting health and social needs; and Matters Most centers what the patient values. In this paper, the framework is applied to incretin therapy and obesity medication decisions for older adults.
The report describes the article as a practical, case-based approach. It does not provide trial results or a new medication approval. Its focus is how clinicians can consider the potential benefits of treatment alongside vulnerabilities that may be especially relevant in later life.
“Safe prescribing requires pretreatment assessment of functional status, nutritional adequacy and cognitive impairment.”
— The paper’s authors, as summarized in the Medical Xpress report
Evidence Gaps and Individual Decisions
The report does not give detailed case outcomes, patient numbers, or estimates of how often the risks identified in the framework occur. It also does not establish which older adults are most likely to benefit from a specific drug or which medication and dose are appropriate for an individual. The source identifies older adults’ underrepresentation in clinical trials but does not quantify the gap or describe particular trials.
It remains unclear from the report how the framework may affect prescribing in practice, whether it has been adopted by health systems, or what patient outcomes might follow. The recommendations should not be read as evidence that a drug is suitable for every older adult. Clinical decisions remain individual and depend on a patient’s health, medication profile, goals and clinician assessment.
Applying the Framework in Practice
The paper offers clinicians a structure to use when evaluating obesity medication treatment, beginning with pretreatment assessment and considering supportive care. The next practical step is for clinicians and patients to discuss personal goals, functional health and nutrition, then decide whether medication and any additional professional support fit the person’s circumstances.
The source report does not announce a rollout, implementation deadline or follow-up study. Further evidence on outcomes in older adults would help clarify how benefits and risks vary across this population. Until then, the framework’s recommendations are guidance for individualized prescribing, not a substitute for clinical judgment.
Key Questions
What did the American Geriatrics Society publish?
The AGS published a case-based framework for clinicians considering obesity medications in older adults. It applies the Geriatrics 5Ms to incretin therapy and patient-centered prescribing.
What does the 5Ms framework cover?
The five areas are Mind, Mobility, Medications, Multicomplexity and Matters Most. They prompt clinicians to consider cognition, function, drug treatment, complex needs and the patient’s priorities.
What should clinicians assess before treatment?
The paper recommends assessing functional status, nutritional adequacy and cognitive impairment. It also highlights frailty, sarcopenia, lean muscle loss, malnutrition and dehydration as considerations.
Does the framework say all older adults should take obesity medication?
No. It provides a way to structure individualized prescribing decisions; it does not recommend medication for every older adult or establish that a particular drug is suitable for everyone.
What supportive measures does the paper discuss?
The authors recommend considering resistance training and adequate dietary protein alongside medication. Some patients may benefit from a team approach involving nutrition, physical therapy, fitness and behavioral health professionals.
Source: medicalxpress.com
